OBP-004 / OncoBone Therapeutics - LARVOL DELTA

Inhibiting CDK9/13 decreases progression of multiple myeloma and myeloma-induced bone disease in preclinical studies (AACR 2026) - "OBP-004 showed significantly stronger tumor growth inhibition than bortezomib and decreased cancer-induced bone loss similarly to zoledronic acid.We conclude that CDK9/CDK13 is a potential target in hematological malignancies including MM. By targeting CDK9/13, it is possible to affect both tumor growth and cancer-induced bone loss."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • Solid Tumor • CDK13 • CDK9

A highly potent selective CDK9 inhibitor OBP-004 reduces metastatic tumor burden in bone, brain, lung and lymph nodes and decreases growth of triple-negative breast cancer cells in bone (AACR 2025) - "In the MV4-11 model, OBP-004 showed strong decrease of bone, brain, lung and lymph node metastases. In the intratibial 4T1 model, OBP-004 decreased tumor growth in bone from day 10 forward, bone pain at day 14, and cancer-induced bone loss at day 21.We conclude that the highly potent selective CDK9 inhibitor OBP-004 reduces metastatic tumor growth in bone, brain, lung and lymph nodes and decreases metastatic growth of TNBC cells in bone microenvironment, bone pain and cancer-induced bone loss in an aggressive preclinical TNBC model."

Metastases • Acute Myelogenous Leukemia • Breast Cancer • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • Triple Negative Breast Cancer

OBP-004, a novel small-molecule dual inhibitor of CDK9/13, reduces bone, brain, lung and lymph node metastases in vivo, with highest potency on bone metastases (AACR-NCI-EORTC 2025) - "We conclude that OBP-004, a highly potent and selective dual inhibitor of CDK9/CDK13, is a promising preclinical drug candidate especially for the treatment of bone metastatic TNBC and CRPC. These results indicate that OBP-004 affects both tumor growth and cancer-induced bone changes, and the observed decrease in bone pain indicates potential for increasing the quality of life of bone metastatic patients."

Preclinical • Acute Myelogenous Leukemia • Breast Cancer • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Oncology • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer • CDK13 • CDK9

OBP-004, a highly potent selective small-molecule dual inhibitor of CDK9/13 reduces bone metastatic growth, cancer-induced bone loss and bone pain of triple-negative breast cancer and castration-resistant prostate cancer in preclinical models (ASBMR 2025) - No abstract available

Metastases • Preclinical • Breast Cancer • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Musculoskeletal Pain • Oncology • Pain • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer • CDK9